Form 4: Corcept Therapeutics Executive Sells Shares and Transfers Stock in SEC Filing

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, sold 2,609 shares and gifted 300 shares of company stock, according to a recent SEC Form 4 filing.

Summary

• Gary Charles Robb, the Chief Business Officer of Corcept Therapeutics, executed a sale of 2,609 shares of common stock at a price of $56.20 per share on November 22, 2024.
• On the same day, Mr. Robb also gifted 300 shares of common stock.
• Following these transactions, Mr. Robb directly owns 19,863 shares of Corcept Therapeutics stock.
• Additionally, Mr. Robb indirectly owns 9,665 shares through a custodial account for his child.
• The filing also notes that Mr. Robb holds unvested restricted stock awards that will vest on the one-year anniversary of their grant dates.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment. It reports a routine transaction by an executive, which is neither overwhelmingly positive nor negative. The sale could be seen as slightly negative, but it's not a large sale and could be for personal reasons.

Negatives

• The sale of 2,609 shares by a high-ranking executive could be interpreted negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence in the company's future performance, although this is not always the case.
• The market may react negatively to the sale, potentially impacting the stock price.

Industry Context

SEC Form 4 filings are a standard part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Executive stock sales are common across the pharmaceutical and biotech industries, and the size of this sale is not unusual for a company of Corcept's size.
• Other companies such as AbbVie, Amgen, and Gilead Sciences also have executives who regularly trade company stock, and these transactions are also reported via SEC Form 4 filings.

Stakeholder Impact

• Shareholders may react to the stock sale, potentially causing a minor fluctuation in the stock price.
• The impact on other stakeholders is likely to be minimal.

Key Dates

Keywords

SEC Form 4, Corcept Therapeutics, stock sale, executive, Gary Charles Robb, share transfer, insider trading, CORT